Lindsey Roeker, MD, Discusses Potential for BTK Inhibition Plus Umbralisib/Ublituximab in CLL

News
Video
Conference|ASH Annual Meeting & Exposition: Leukemia

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

At the 2021 American Society of Hematology Annual Meeting, CancerNetwork® spoke with Lindsey Roeker, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center in New York, about why umbralisib (Ukoniq) and ublituximab (TGTX-1101) plus ibrutinib (Imbruvica) is a potentially important regimen and how it can help improve treatment for those with chronic lymphocytic leukemia.

Transcript:

I think that the combination of ibrutinib, umbralisib, and ublituximab is a really promising one. This might allow us a step-up approach that identifies patients who are in need of the combination therapy after exposure to ibrutinib monotherapy. We’re still trying to figure out who the ideal patient is for the combination approach [with the] understanding that there is added toxicity with the drugs together, but there’s also added efficacy. How do we optimally select those patients? This is a novel treatment design that allows us to really identify a patient population that might benefit most.

Reference

Roeker L, Leslie L, Soumerai J, et al. A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)- driven, time-limited approach. Presented at the 2021 American Society of Hematology Annual Meeting. December 11-14, 2021. Abstract 395. https://bit.ly/3sKm471

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
Related Content
Clinical Implications Remain After Dasatinib CRL in CML/ALL

Clinical Implications Remain After Dasatinib CRL in CML/ALL

Ariana Pelosci
October 28th 2025
Article

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Results from the phase 1/2 AUGMENT-101 trial support the FDA’s decision for approving revumenib in this NPM1-mutated, relapsed/refractory AML population.

FDA Approves Revumenib in R/R NPM1-Mutant AML

Tim Cortese
October 24th 2025
Article

Results from the phase 1/2 AUGMENT-101 trial support the FDA’s decision for approving revumenib in this NPM1-mutated, relapsed/refractory AML population.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

FDA Issues CRL for Dasatinib in CML/ALL

FDA Issues CRL for Dasatinib in CML/ALL

Ariana Pelosci
October 20th 2025
Article

Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.

A 13-week Good Laboratory Practice toxicity study demonstrated that UB-VV111 was well-tolerated in CD34-humanized mice.

FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies

Tim Cortese
October 1st 2025
Article

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.